Innate and adaptive immune cells in the tumor microenvironment
By T. Gajewski, H. Schreiber, yang-xin fu. Nature Immunology, 2013
3,825 citations recorded by the source corpus.
Most tumor cells express antigens that can mediate recognition by host CD8+ T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell–inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system–suppressive pathways. The other major phenotype lacks this T cell–inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/bddd0e69da868f9cfc1429618641a5ea372a94b9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control (2018, background): “…immune cells comprise lymphocytes, such as T cells, B, cells and natural killer (NK) cells, and diverse populations of myeloid cells, including granulocytes, monocytes, macrophages, and dendritic cells (DCs) (Gajewski et al., 2013; Hanahan and Weinberg, 2011; Palucka and Coussens, 2016).”
- STING: infection, inflammation and cancer (2015, positive): “Thus, loss of STING may enable damaged cells to escape tumour immunosurveillance [80] [81] [82] .”
- Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors (2016, neutral): “For example, even when redirected to recognize tumors, T cells have limited capabilities to overcome the immunosuppressive microenvironment of the tumor (Gajewski et al., 2013).”
- Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front (2019, background): “Naturally, the question arises of how a tumor avoids immune action, such as by T cell exclusion (Joyce and Fearon, 2015) or increased prevalence of certain CTs, including Treg cells, macrophages, and myeloid-derived suppressor cells (Gajewski et al., 2013; Hanahan and Weinberg, 2011; Kumar et al., 2”
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015, background): “A possible explanation is that negative immune regulators are present as part of a normal feedback loop reacting to an active and ongoing antitumor immune response, which therefore potentially defines tumors that are more immunogenic [25].”
- Immune escape mechanisms as a guide for cancer immunotherapy (2014, background): “Immune signatures for cancer immunotherapy are actively being explored across many clinical studies (8).”
- Genetics and biology of prostate cancer (2018, background): “Lymphocytes are key cellular components in the mammalian adaptive immune system that protect the host from infectious pathogens, with various lymphocyte subtypes playing central roles in cancer biology and treatment (Gajewski et al. 2013).”
- Impact of Obesity and Metabolic Syndrome on Immunity. (2016, background): “Given the important role of the immune system in cancer surveillance (129), it is likely that obesity-related impairments in immunity may contribute to the increased risk of developing cancer.”